IgG Segment to Emerge as Prominent Intravenous Immunoglobulin Type Segment According to our latest study, titled "Intravenous Immunoglobulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Type, Application, Distribution Channel, End User, and Geography," the market is projected to reach US$ 18,672.55 million by 2028 from value of US$ 11,206.54 million in 2021. It is expected to grow at a CAGR of 7.6% from 2022 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

The COVID-19 pandemic improved the risk of COVID-19 infection among people suffering with immunodeficient disorders. Patients with underlying immunodeficient disorders, like hypogammaglobulinemia and specific antibody deficiency (SDA) were considered at greater risk of COVID-19 infection and more likely to have higher morbidity and mortality. Also, only essential procedures were allowed in hospitals during the lockdown which interrupted the IVIg therapy among patients receiving the same. Additionally, to develop effective treatment for COVID-19, key players and government of various countries in middle east collaborated during the COVID-19 pandemic. For instance, in 2020, Kamada announced that it has signed an agreement with the Israeli Ministry of Health (MoH) to supply its anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin (IgG) product for the treatment of coronavirus (COVID-19) patients in Israel. The use of this investigational product was regulated by the MoH. Thus, the COVID-19 pandemic positively impacted the intravenous immunoglobulin market.

Based on the type, the intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment is likely to account for a larger market share during the forecast period. By application, the market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. The hypogammaglobulinemia segment held a larger market share in 2021 and is projected to continue its dominance during the forecast period. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others. By end user, the market is segmented into hospitals, specialty clinics, and others. The hospitals segment held the largest market share in 2021 and is likely to continue its dominance during the forecast period.

Increasing Geriatric Population Drives Intravenous Immunoglobulin Market

As per the report 2020 PROFILE OF OLDER AMERICANS, in 2019, in the US, the population aged 65 and above was 54.1 million-30 million women and 24.1 million men. In 2019, 16% of the total population was aged 65 and above, and it is expected to increase to 21.6% by 2040. Since 2009, aged population has increased by 14.4 million (or 36%) in the US.

As per the Eurostat, in 2019, there were around 90.4 million older people (aged 65 years or above) living in the EU-27. As per the United Nations Population Division, World Population Prospects 2019, Asian and European countries have some of the world's oldest populations aged 65 and more. Japan being at top with 28%, followed by Italy at 23%. Further, Finland, Portugal, and Greece are among the top five countries with aged population under 22%.

Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person's body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve use of IVIg. Thus, the increase in geriatric population across the globe is bolstering the intravenous immunoglobulin market.

Based on geography, the global intravenous immunoglobulin market is primarily segmented into North America, Europe, Asia Pacific, Middle East and Africa (MEA), and South and Central America. The market in North America is further segmented into the US, Canada, and Mexico. The Europe market is sub-segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market in Asia Pacific is sub-segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. The intravenous immunoglobulin market in the MEA is further segmented into South Africa, Saudi Arabia, the UAE, and the Rest of the MEA. The South and Central America market is sub-segmented into Brazil, Argentina, and the Rest of South and Central America.

Companies such as Takeda Pharmaceutical Company Limited; Grifols, S.A.; Pfizer Inc.; ADMA Biologics Inc.; Bio Products Laboratory Ltd.; Shanghai RAAS; Octapharma AG; Kedrion S.p.A; CSL Behring (CSL Limited); and Prothya Biosolutions B.V. are engaged in the strategic activities for intravenous immunoglobulin market products.

In April 2020, Octapharma collaborated with CSL, Takeda, BPL, Biotest, and LFB to investigate the possibility of treating COVID-19 with plasma-derived hyper immune immunoglobulin.

In April 2021, the U.S. Food and Drug Administration (FDA) has granted approval for the Company's expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool for the manufacture of Intravenous Immune Globulin (IVIg).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com